Swiss Medical Weekly Chooses Xpublisher for JATS XML-Based Publications
Xpublisher is the new publishing system for medical journal Swiss Medical Weekly (SMW). Working with Xpublisher enables SMW to publish JATS XML-based scientific articles online swiftly and reliably.
Swiss Medical Weekly uses Xpublisher
By choosing Xpublisher, the journal is pursuing a consistent XML and content-first approach to preparing media-independent content and automating its publication. The software’s integrated Xeditor assists the editorial team in formatting scientific articles based on the JATS XML article authoring schema. Xpublisher then facilitates a conversion of the XML data, customized for SMW, into an HTML format, which SMW uses for online publication through the CMS "Open Journal Systems" (OJS). “In parallel with migrating our website to Open Journal Systems, we were very interested in establishing an XML-first workflow based on the JATS format. We have analyzed several solutions and are absolutely convinced by Xpublisher and Xeditor. With the help of the Xpublisher GmbH team, we designed a customized system that clearly maps our processes and helps us to create all our articles in valid JATS XML. Since Xpublisher provided a JATS format, we not only imported the content, we also imported the metadata of every single previous article in our extensive archive into OJS completely automatically,” reports a pleased Dr. Natalie Marty, managing director of the SMW supporting association. The Xpublisher editorial system is available as SaaS in a highly secure cloud environment.
About Swiss Medical Weekly
Founded in 1871, the Swiss Medical Weekly is a medical journal with a long tradition. The SMW is a pioneer of the Diamond Open Access model. Even before the publication of the Berlin Declaration on Open Access, the journal had already introduced free open online access to all published articles, without charging authors publication fees. The articles are reviewed according to strict scientific criteria and published regularly online. The journal is published by the non-profit organization “Trägerverein Swiss Medical Weekly,” which aims to enable and advance publishing based on the Diamond model. For more information, visit www.smw.ch.
About Xpublisher GmbH
Xpublisher GmbH is a leading provider in the multichannel publishing space, delivering intuitive products for creating, managing, and automating magazine, book, and documentation publishing with Xeditor and Xpublisher. Xpublisher was founded in 2009 and is based in Munich, Germany. The company operates a US subsidiary and has been part of the Fabasoft Group since 2019. Numerous leading international companies and organizations in the publishing, aerospace, technology, education, and public administration sectors together with a host of other industries have already placed their trust in Xpublisher’s products.
For more information, visit www.xpublisher.com or follow us on LinkedIn and Twitter @Xpublisher.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005220/en/
Contact information
Press contact
Julia Schnelldorfer
+49 162 2166891
julia.schnelldorfer@xpublisher.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom